Sinomenine hydrochloride

Sinomenine hydrochloride (Cucoline hydrochloride), an alkaloid extracted from Sinomenium acutum, is a blocker of the NF-κB activation[1]. Sinomenine also is an activator of μ-opioid receptor[2].

Product Specifications

CAS Number

[6080-33-7]

Product Name Alternative

Cucoline hydrochloride

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Apoptosis; Autophagy; NF-κB; Opioid Receptor

Type

Natural Products

Related Pathways

Apoptosis; Autophagy; GPCR/G Protein; Neuronal Signaling; NF-κB

Applications

Cancer-programmed cell death

Field of Research

Cancer; Inflammation/Immunology; Neurological Disease

Assay Protocol

https://www.medchemexpress.com/Sinomenine_hydrochloride.html

Purity

99.89

Solubility

DMSO : 100 mg/mL (ultrasonic; warming) |H2O : 16.67 mg/mL (ultrasonic)

Smiles

OC(C1=C2C[C@@]3([H])[C@](C=C4OC)([H])[C@@]1(CCN3C)CC4=O)=C(C=C2)OC.Cl

Molecular Formula

C19H24ClNO4

Molecular Weight

365.85

Precautions

H302, H315, H319, H335

References & Citations

[1]Song L, et al. Sinomenine inhibits breast cancer cell invasion and migration by suppressing NF-κB activation mediated by IL-4/miR-324-5p/CUEDC2 axis. Biochem Biophys Res Commun. 2015 Aug 28;464 (3) :705-10.|[2]Gao T, et al. Analgesic effect of sinomenine in rodents after inflammation and nerve injury. Eur J Pharmacol. 2013 Dec 5;721 (1-3) :5-11.|[3]Zhu Q, et al. Antinociceptive effects of sinomenine in a rat model of neuropathic pain. Sci Rep. 2014 Dec 1;4:7270.|[4]Wang MH, et al. Activation of opioid mu-receptor by sinomenine in cell and mice.Neurosci Lett. 2008 Oct 10;443 (3) :209-12.

Shipping Conditions

Room Temperature

Storage Conditions

4°C (Powder, sealed storage, away from moisture)

Scientific Category

Natural Products

Clinical Information

Launched

Isoform

NF-κB; μ Opioid Receptor/MOR

Citation 01

BioRxiv. 2024 Apr 3:2023.06.02.542933.|Free Radic Biol Med. 2018 Aug 20:124:205-213.|Immun Inflamm Dis. 2024 Jun;12 (6) :e1271.|J Dairy Sci. 2025 Nov 7:S0022-0302 (25) 00911-7.|Acta Pharm Sin B. 2021 Nov;11 (11) :3465-3480.|Chem Biol Drug Des. 2023 Sep;102 (3) :434-443.|Drug Des Devel Ther. 2024 Aug 6:18:3523-3545.|Exp Ther Med. 2021 Jun;21 (6) :647.|Heliyon. 2024 Jun 24;10 (13) :e33314.|J Inflamm Res. 2023 Oct 20:16:4777-4791.|Naunyn Schmiedebergs Arch Pharmacol. 2025 May 17.|Phytomedicine. 2025 May:140:156484.|Phytother Res. 2023 Aug;37 (8) :3323-3341.|PLoS Biol. 2024 Jun 27;22 (6) :e3002672.|World J Stem Cells. 2024 May 26.